+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncolytic Virus Manufacturing & Development Services Market - Global Forecast 2026-2032- Product Image
Oncolytic Virus Manufacturing & Development Services Market - Global Forecast 2026-2032- Product Image
Sale

Oncolytic Virus Manufacturing & Development Services Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6116725
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oncolytic Virus Manufacturing & Development Services Market is projected to reach USD 376.37 Million in 2026. It is expected to continue growing at a CAGR of 6.24%, reaching USD 550.61 Million by 2032.

Oncolytic Virus Manufacturing and Development Services: Executive Overview

Oncolytic virus manufacturing and development services support the design, testing, process development, production, analytical characterization, and regulatory preparation of viral medicines intended to selectively infect and destroy tumor cells. The field combines virology, cell biology, genetic engineering, bioprocessing, quality control, and clinical development. Its complexity arises from the need to preserve viral potency while controlling replication competence, product consistency, sterility, genomic integrity, and patient safety across development stages.

Manufacturing Complexity Is Reshaping Oncolytic Virus Development

The landscape is shifting from laboratory-scale experimentation toward more standardized, reproducible, and scalable development pathways. Sponsors increasingly need integrated capabilities spanning construct design, cell-bank development, upstream and downstream processing, formulation, stability testing, release assays, and clinical supply. Platform choices are also being evaluated against manufacturability, biosafety requirements, dosing route, combination-therapy compatibility, and the ability to generate comparable material across sites and stages of development.

Regulatory expectations are encouraging earlier attention to critical quality attributes, adventitious-agent controls, potency assays, and comparability plans. At the same time, improvements in closed processing, single-use systems, automation, and process analytical technologies are helping address contamination risk and batch variability. These shifts make technical transfer, documentation, and quality-by-design practices increasingly important to development continuity.

Artificial Intelligence Is Accelerating Design, Analytics, and Process Control

Artificial intelligence can support oncolytic virus development by analyzing biological datasets, identifying candidate genetic modifications, prioritizing tumor-targeting strategies, and helping model interactions between viral constructs and tumor microenvironments. It can also assist with image-based potency measurements, assay signal interpretation, deviation review, raw-material monitoring, and predictive maintenance in manufacturing operations.

The practical value of these tools depends on representative datasets, validated workflows, traceable model outputs, and effective human oversight. AI-generated hypotheses still require laboratory confirmation, while algorithmic decisions used in quality or regulatory contexts must be explainable and controlled. Organizations that combine AI with robust data governance, standardized experimental records, and validated analytical methods are better positioned to improve development speed without compromising product quality or patient safety.

Regional Insights: Different Infrastructure and Regulatory Conditions Shape Execution

North America benefits from mature biotechnology infrastructure, specialized clinical development capabilities, and established regulatory pathways, while Latin America presents opportunities alongside differences in trial operations, supply logistics, and specialized manufacturing access. Europe combines advanced research networks with detailed requirements for quality, biosafety, and cross-border clinical supply. The Middle East is building life-science capacity, with partnerships and technology transfer remaining important for complex viral products.

Africa’s development environment varies substantially by country, making local regulatory coordination, cold-chain reliability, clinical-site capability, and workforce development central considerations. Asia-Pacific includes highly developed biomanufacturing and pharmaceutical ecosystems as well as rapidly expanding research capacity. Across all regions, sponsors must align technology transfer, biosafety documentation, release testing, import or export controls, and clinical-supply planning with local requirements rather than assuming a single global operating model.

Group Insights: Economic and Security Blocs Influence Collaboration and Access

ASEAN offers a diverse set of regulatory systems and manufacturing capabilities, so regional programs benefit from early harmonization work and country-specific implementation plans. BRICS members provide broad scientific, clinical, and industrial capabilities but require careful navigation of different approval systems, supply networks, and technology-transfer conditions. The European Union supports coordinated scientific and regulatory activity, while still requiring attention to national site operations and cross-border logistics.

The G7 combines strong biomedical research, advanced quality systems, and sophisticated clinical infrastructure, creating a demanding environment for evidence generation and manufacturing compliance. GCC countries are investing in healthcare and biopharmaceutical capabilities, with partnerships, workforce development, and localized supply strategies supporting adoption. NATO members span varied national systems, but shared emphasis on resilience, biosafety, and secure supply chains can inform risk-management planning for critical manufacturing inputs and clinical materials.

Country Insights: Capabilities and Execution Priorities Differ Across Key Markets

Australia offers strong clinical research capabilities and a regulated development environment, while Brazil and Mexico require careful planning for regulatory submissions, trial operations, and distribution across large territories. Canada supports advanced biomedical research and clinical development, and the United States provides extensive expertise in translational research, specialized manufacturing, and regulatory preparation. In Europe, France, Germany, Italy, Spain, and the United Kingdom combine established research and healthcare systems with distinct national requirements for sites, procurement, and implementation.

China has substantial biopharmaceutical manufacturing and research capacity, but development programs must address local regulatory expectations, data requirements, and technology-transfer considerations. India offers expanding bioprocessing and clinical capabilities, with quality-system maturity and specialized viral manufacturing remaining important selection criteria. Japan emphasizes rigorous quality, safety, and regulatory documentation, while South Korea has advanced biomanufacturing infrastructure. Russia presents a more complex operating environment in which regulatory, logistics, partnership, and supply-continuity risks require heightened assessment.

Action Priorities for Leaders Building Reliable Oncolytic Virus Programs

Industry leaders should select development and manufacturing partners against a documented capability matrix covering viral construct experience, biosafety controls, cell substrates, scale-up evidence, potency testing, analytical validation, quality systems, and regulatory support. Critical quality attributes and acceptance criteria should be defined early, with comparability plans established before process changes, site transfers, or scale transitions occur.

Programs should also build redundancy for high-risk raw materials, specialized assays, and clinical-supply steps; use stage-appropriate process characterization; and maintain integrated oversight across research, manufacturing, quality, and clinical teams. Regional execution plans should address cold-chain requirements, import controls, release responsibilities, and emergency supply options. AI adoption should proceed through governed pilots tied to measurable outcomes, validated data, cybersecurity controls, and documented human review.

Research Methodology for the Executive Summary

This executive summary uses the defined market scope of oncolytic virus manufacturing and development services and organizes findings around development workflows, manufacturing requirements, regulatory considerations, technology adoption, and geographic operating conditions. The assessment distinguishes technical capabilities from commercial claims and focuses on verifiable industry characteristics rather than market estimates, shares, or forecasts.

Regional, group, and country observations are synthesized from the stated geographic coverage and from broadly documented differences in biotechnology infrastructure, regulatory systems, clinical research capacity, supply-chain conditions, and biomanufacturing maturity. Because capabilities can differ by institution and change over time, country-level conclusions should be validated against current regulations, facility qualifications, partnership records, and program-specific due diligence before implementation.

Conclusion: Execution Discipline Will Determine Oncolytic Virus Program Readiness

Oncolytic virus development is moving toward integrated, quality-led operating models that connect construct design with manufacturability, analytical control, clinical supply, and regulatory strategy from the outset. The strongest programs will treat process consistency, potency measurement, biosafety, comparability, and supply resilience as development priorities rather than late-stage compliance tasks.

Regional and country differences make flexible execution essential, while AI can enhance discovery and operations when deployed within validated and well-governed systems. Leaders that combine specialized expertise, early quality planning, resilient partnerships, and disciplined technology transfer can improve the reliability of development decisions and the readiness of oncolytic virus programs for clinical advancement.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oncolytic Virus Manufacturing & Development Services Market, by Service Type
7.1. Introduction
7.2. Analytical Services
7.3. Cell Line Development
7.4. Fill & Finish
7.5. Manufacturing
7.5.1. Clinical Manufacturing
7.5.2. Commercial Manufacturing
7.5.3. Preclinical Manufacturing
7.6. Process Development
7.7. Purification
7.8. Quality Control
7.9. Regulatory Support
8. Oncolytic Virus Manufacturing & Development Services Market, by Scale
8.1. Introduction
8.2. Clinical
8.2.1. Phase I/II
8.2.2. Phase III
8.3. Commercial
8.4. Preclinical
9. Oncolytic Virus Manufacturing & Development Services Market, by Virus Type
9.1. Introduction
9.2. Adenovirus
9.3. Herpes Simplex Virus
9.4. Measles Virus
9.5. Newcastle Disease Virus
9.6. Reovirus
9.7. Vaccinia Virus
10. Oncolytic Virus Manufacturing & Development Services Market, by Contract Type
10.1. Introduction
10.2. Collaborative Research
10.3. Fee-for-Service
10.4. Joint Ventures
10.5. License Agreements
11. Oncolytic Virus Manufacturing & Development Services Market, by End User
11.1. Introduction
11.2. Academic Research Institutes
11.3. Biotech Companies
11.4. Contract Research Organizations
11.5. Hospitals
11.6. Pharmaceutical Companies
12. Oncolytic Virus Manufacturing & Development Services Market, by Application
12.1. Introduction
12.2. Hematological Malignancies
12.2.1. Leukemia
12.2.2. Lymphoma
12.2.3. Multiple Myeloma
12.3. Solid Tumors
12.3.1. Breast Cancer
12.3.2. Colorectal Cancer
12.3.3. Lung Cancer
12.3.4. Melanoma
13. Oncolytic Virus Manufacturing & Development Services Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Oncolytic Virus Manufacturing & Development Services Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Oncolytic Virus Manufacturing & Development Services Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. ABL, Inc.
17.2. AGC Biologics, Inc.
17.3. Amgen Inc.
17.4. Catalent, Inc.
17.5. Creative Biogene Co., Ltd.
17.6. Danaher Corporation
17.7. Elise Biopharma GmbH
17.8. Fujifilm Diosynth Biotechnologies
17.9. IDT Biologika GmbH
17.10. Lonza Group AG
17.11. Merck KGaA
17.12. Oncolys BioPharma, Inc.
17.13. Oncolytics Biotech Inc.
17.14. Oxford Biomedica plc
17.15. PsiOxus Therapeutics Ltd.
17.16. Recipharm AB
17.17. Replimune Group, Inc.
17.18. Sartorius AG
17.19. SillaJen, Inc.
17.20. Theriva Biologics, Inc.
17.21. Thermo Fisher Scientific Inc.
17.22. TILT Biotherapeutics Oy
17.23. Transgene S.A.
17.24. Viralytics Ltd.
17.25. WuXi AppTec Co., Ltd.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Oncolytic Virus Manufacturing & Development Services Market, Years Considered for the Study
FIGURE 2. Global Oncolytic Virus Manufacturing & Development Services Market, Research Design
FIGURE 3. Global Oncolytic Virus Manufacturing & Development Services Market, Research Framework
FIGURE 4. Global Oncolytic Virus Manufacturing & Development Services Market, Data Triangulation
FIGURE 5. Global Oncolytic Virus Manufacturing & Development Services Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2025 vs 2032 (%)
FIGURE 7. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2025 vs 2032 (%)
FIGURE 9. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2025 vs 2032 (%)
FIGURE 11. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2025 vs 2032 (%)
FIGURE 13. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2025 vs 2032 (%)
FIGURE 17. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Oncolytic Virus Manufacturing & Development Services Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Oncolytic Virus Manufacturing & Development Services Market Segmentation & Coverage
TABLE 2. Global Oncolytic Virus Manufacturing & Development Services Market Size, 2017-2032 (USD Million)
TABLE 3. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 4. Global Analytical Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Analytical Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Analytical Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Cell Line Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Cell Line Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Cell Line Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Fill & Finish Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Fill & Finish Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Fill & Finish Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Clinical Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Clinical Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Clinical Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Commercial Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Commercial Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Commercial Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Preclinical Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Preclinical Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Preclinical Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Process Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Process Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Process Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Purification Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Purification Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Purification Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Quality Control Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Quality Control Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Quality Control Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Regulatory Support Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Regulatory Support Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Regulatory Support Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 38. Global Clinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Clinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Clinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Phase I/II Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Phase I/II Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Phase I/II Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Commercial Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Commercial Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Commercial Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 54. Global Adenovirus Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Adenovirus Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Adenovirus Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Herpes Simplex Virus Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Herpes Simplex Virus Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Herpes Simplex Virus Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Measles Virus Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Measles Virus Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Measles Virus Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Newcastle Disease Virus Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Newcastle Disease Virus Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Newcastle Disease Virus Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Reovirus Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Reovirus Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Reovirus Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Vaccinia Virus Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Vaccinia Virus Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Vaccinia Virus Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 73. Global Collaborative Research Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Collaborative Research Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Collaborative Research Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Fee-for-Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Fee-for-Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Fee-for-Service Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Joint Ventures Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Joint Ventures Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Joint Ventures Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global License Agreements Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global License Agreements Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global License Agreements Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. Global Academic Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Academic Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Academic Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Biotech Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Biotech Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Biotech Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 102. Global Hematological Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Hematological Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Hematological Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Leukemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Leukemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Leukemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global Lymphoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Global Lymphoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. Global Lymphoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 111. Global Multiple Myeloma Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Multiple Myeloma Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Multiple Myeloma Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 120. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 123. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 124. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 126. Global Melanoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 127. Global Melanoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 128. Global Melanoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 129. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 130. Asia-Pacific Oncolytic Virus Manufacturing & Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Asia-Pacific Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 132. Asia-Pacific Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 133. Asia-Pacific Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 134. Asia-Pacific Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 135. Asia-Pacific Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 136. Asia-Pacific Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 137. Asia-Pacific Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. Asia-Pacific Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 139. Asia-Pacific Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 140. Asia-Pacific Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 141. North America Oncolytic Virus Manufacturing & Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. North America Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 143. North America Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 144. North America Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 145. North America Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 146. North America Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 147. North America Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 148. North America Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 149. North America Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 150. North America Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 151. North America Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 152. Latin America Oncolytic Virus Manufacturing & Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 153. Latin America Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 154. Latin America Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 155. Latin America Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 156. Latin America Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 157. Latin America Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 158. Latin America Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 159. Latin America Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Latin America Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 161. Latin America Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 162. Latin America Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 163. Europe Oncolytic Virus Manufacturing & Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Europe Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 165. Europe Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 166. Europe Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 167. Europe Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 168. Europe Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 169. Europe Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 170. Europe Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. Europe Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 172. Europe Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 173. Europe Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 174. Middle East Oncolytic Virus Manufacturing & Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 175. Middle East Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 176. Middle East Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 177. Middle East Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 178. Middle East Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 179. Middle East Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 180. Middle East Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 181. Middle East Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 182. Middle East Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 183. Middle East Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 184. Middle East Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 185. Africa Oncolytic Virus Manufacturing & Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 186. Africa Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 187. Africa Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 188. Africa Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 189. Africa Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 190. Africa Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 191. Africa Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 192. Africa Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. Africa Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 194. Africa Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 195. Africa Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 196. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 197. ASEAN Oncolytic Virus Manufacturing & Development Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 198. ASEAN Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 199. ASEAN Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 200. ASEAN Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 201. ASEAN Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 202. ASEAN Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 203. ASEAN Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 204. ASEAN Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. ASEAN Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 206. ASEAN Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 207. ASEAN Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 208. GCC Oncolytic Virus Manufacturing & Development Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 209. GCC Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 210. GCC Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 211. GCC Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 212. GCC Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 213. GCC Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 214. GCC Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 215. GCC Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. GCC Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 217. GCC Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 218. GCC Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 219. European Union Oncolytic Virus Manufacturing & Development Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 220. European Union Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 221. European Union Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 222. European Union Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 223. European Union Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 224. European Union Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 225. European Union Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 226. European Union Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. European Union Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 228. European Union Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 229. European Union Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 230. BRICS Oncolytic Virus Manufacturing & Development Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 231. BRICS Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 232. BRICS Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 233. BRICS Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 234. BRICS Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 235. BRICS Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 236. BRICS Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 237. BRICS Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 238. BRICS Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 239. BRICS Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 240. BRICS Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 241. G7 Oncolytic Virus Manufacturing & Development Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 242. G7 Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 243. G7 Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 244. G7 Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 245. G7 Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 246. G7 Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 247. G7 Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 248. G7 Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 249. G7 Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 250. G7 Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 251. G7 Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 252. NATO Oncolytic Virus Manufacturing & Development Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 253. NATO Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 254. NATO Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 255. NATO Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 256. NATO Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 257. NATO Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 258. NATO Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 259. NATO Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 260. NATO Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 261. NATO Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 262. NATO Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 263. Global Oncolytic Virus Manufacturing & Development Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 264. United States Oncolytic Virus Manufacturing & Development Services Market Size, 2017-2032 (USD Million)
TABLE 265. United States Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 266. United States Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 267. United States Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 268. United States Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 269. United States Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 270. United States Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 271. United States Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. United States Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 273. United States Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 274. United States Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 275. Canada Oncolytic Virus Manufacturing & Development Services Market Size, 2017-2032 (USD Million)
TABLE 276. Canada Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 277. Canada Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 278. Canada Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 279. Canada Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 280. Canada Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 281. Canada Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 282. Canada Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 283. Canada Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 284. Canada Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 285. Canada Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 286. Mexico Oncolytic Virus Manufacturing & Development Services Market Size, 2017-2032 (USD Million)
TABLE 287. Mexico Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 288. Mexico Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 289. Mexico Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 290. Mexico Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 291. Mexico Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 292. Mexico Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Million)
TABLE 293. Mexico Oncolytic Virus Manufacturing & Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 294. Mexico Oncolytic Virus Manufacturing & Development Services Market Size, by Application, 2017-2032 (USD Million)
TABLE 295. Mexico Oncolytic Virus Manufacturing & Development Services Market Size, by Hematological Malignancies, 2017-2032 (USD Million)
TABLE 296. Mexico Oncolytic Virus Manufacturing & Development Services Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 297. Brazil Oncolytic Virus Manufacturing & Development Services Market Size, 2017-2032 (USD Million)
TABLE 298. Brazil Oncolytic Virus Manufacturing & Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 299. Brazil Oncolytic Virus Manufacturing & Development Services Market Size, by Manufacturing, 2017-2032 (USD Million)
TABLE 300. Brazil Oncolytic Virus Manufacturing & Development Services Market Size, by Scale, 2017-2032 (USD Million)
TABLE 301. Brazil Oncolytic Virus Manufacturing & Development Services Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 302. Brazil Oncolytic Virus Manufacturing & Development Services Market Size, by Virus Type, 2017-2032 (USD Million)
TABLE 303. Brazil Oncolytic Virus Manufacturing & Development Services Market Size, by Contract Type, 2017-2032 (USD Mill

Companies Mentioned

  • ABL, Inc.
  • AGC Biologics, Inc.
  • Amgen Inc.
  • Catalent, Inc.
  • Creative Biogene Co., Ltd.
  • Danaher Corporation
  • Elise Biopharma GmbH
  • Fujifilm Diosynth Biotechnologies
  • IDT Biologika GmbH
  • Lonza Group AG
  • Merck KGaA
  • Oncolys BioPharma, Inc.
  • Oncolytics Biotech Inc.
  • Oxford Biomedica plc
  • PsiOxus Therapeutics Ltd.
  • Recipharm AB
  • Replimune Group, Inc.
  • Sartorius AG
  • SillaJen, Inc.
  • Theriva Biologics, Inc.
  • Thermo Fisher Scientific Inc.
  • TILT Biotherapeutics Oy
  • Transgene S.A.
  • Viralytics Ltd.
  • WuXi AppTec Co., Ltd.

Related Topics

Related Reports

Oncolytic Virus Therapies Market - Global Forecast 2026-2032 - Product Image

Oncolytic Virus Therapies Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Immunotherapy Drugs Market - Global Forecast 2026-2032 - Product Image

Immunotherapy Drugs Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Oncolytic Virus Immunotherapy Market Opportunity, Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insight 2031 - Product Image

Oncolytic Virus Immunotherapy Market Opportunity, Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insight 2031

  • Report
  • 410 Pages
  • Global
From
Oncolytic Virus Therapies Market Report by Virus Type, Application, End Use, and Region 2026-2034 - Product Image

Oncolytic Virus Therapies Market Report by Virus Type, Application, End Use, and Region 2026-2034

  • Report
  • 138 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 246 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.